Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/isrn/volume-2017/8404378/figures/8404378.fig.003a.svgz" name="8404378.fig.003a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Showing SF36 vitality/energy scores for adult patients before and after the treatment</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/isrn/volume-2017/8404378/figures/8404378.fig.003b.svgz" name="8404378.fig.003b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Showing SF36 social functioning scores for the adult patients before and after the treatment</td></tr></table>

International Scholarly Research Notices

fig3

Figure 3

Figure 3: Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex 